Exosome Diagnostics raises $27 million in series B

Exosome Diagnostics Inc. (New York, N.Y.) raised $27 million in the initial close of a series B round co-led by new investors Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN); and Arcus Ventures. New investors Tiger Partners; CD Ventures; and Monashee Capital also participated, along with existing investors NGN Capital and Forbion Capital Partners. Exosome said it could raise up to $40 million in the round. Arcus' Steven Soignet will join Exosome's board.

Exosome and Qiagen are partnered to develop and commercialize co-branded kits to capture and process RNA and DNA from biofluid exosomes and other microvesicles. In January, the partners expanded the deal to include development of a blood-based, molecular in vitro diagnostic based on exosomes to detect mutations of an undisclosed gene associated with non-small cell lung cancer (NSCLC) and other malignancies. ...